Fennec Pharmaceuticals to Report First Quarter 2023 Financial Results on May 11, 2023
08 5월 2023 - 7:15PM
Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial
stage specialty pharmaceutical company, today announced that the
Company will release its first quarter 2023 financial results
before the opening of the U.S. financial markets on Thursday, May
11, 2023. Management will host a conference call and webcast that
day to discuss the Company’s financial and business results.
Conference Call &
Webcast Detail:Date: Thursday, May 11,
2023Time: 8:30 a.m. Eastern
TimeLink: https://register.vevent.com/register/BIda2814a842e34d0d825731a73c51d74d |
|
To access the conference call, please register
using https://register.vevent.com/register/BIda2814a842e34d0d825731a73c51d74d.
Upon registration, a dial-in number and unique PIN will be provided
to join the call. To access the live webcast link, log
onto www.fennepharma.com and proceed to the News &
Events / Event Calendar page under the Investors & Media
heading. Please connect to the company’s website at least 15
minutes prior to the conference call to ensure adequate time for
any software download that may be required to listen to the
webcast. A webcast replay of the conference call will also be
archived on www.fennecpharma.com for thirty days.
About Fennec
PharmaceuticalsFennec Pharmaceuticals Inc. is a specialty
pharmaceutical company focused on the development and
commercialization of PEDMARK® to reduce the risk of
platinum-induced ototoxicity in pediatric patients. Further,
PEDMARK received FDA approval in September 2022 and has received
Orphan Drug Designation in the U.S. Fennec has a license agreement
with Oregon Health and Science University (OHSU) for exclusive
worldwide license rights to intellectual property directed to
sodium thiosulfate and its use for chemoprotection, including the
reduction of risk of ototoxicity induced by platinum chemotherapy,
in humans. For more information, please visit
www.fennecpharma.com.
For further information, please
contact:
Investors:Robert AndradeChief Financial
OfficerFennec Pharmaceuticals Inc.+1 919-246-5299
Corporate and Media:Lindsay Rocco Elixir Health
Public Relations+1 862-596-1304lrocco@elixirhealthpr.com
Fennec Pharmaceuticals (NASDAQ:FENC)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Fennec Pharmaceuticals (NASDAQ:FENC)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024